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Introduction
The continuous interest in glycogen phosphorylase inhibitors (GPIs) is primarily derived from the antihyperglycemic potential of such molecules involving their possible application in the medication of patients with type II diabetes. 1 On the other hand, inhibition of glycogen phosphorylase (GP) enzymes has also become an investigational approach in the context of other diseases such as ischemic lesions 2e5 and tumors. 6e10 The inhibitors targeting the seven binding sites of GP (catalytic, inhibitor, allosteric, new allosteric, glycogen storage, benzimidazole 11 and the recently discovered quercetin binding site 12 ) show a large molecular diversity. 13e17 Among them various glucose derivatives bind mostly to the catalytic site of the enzyme. 18, 19 At present, N-acyl-b-D-glucopyranosylamines, N-acyl-N 0 -b-D-glucopyranosyl ureas, glucopyranosylidene-spiro-heterocycles as well as N-and C-glucosylated heterocycles (see Chart 1 for some important representatives of the latter e.g., 1e7, 13e20) belong to the most potent classes of this inhibitor family displaying their activity in or below the low micromolar range against rabbit muscle GPb (RMGPb). 17e19 X-ray crystallographic studies on the binding modes of several of these molecules elucidated their increased binding strengths in comparison to that of D-glucose (K i ¼1.7 and 7.4 mM for the a and b anomers, 20 respectively). Besides the ideal fit of the glucose part of these inhibitors in the active site, the strong binding must be ascribed to the H-bonding capacities of the aglycons as well as van der Waals interactions of an aromatic appendage (if present) in the so-called b-channel of the enzyme. 13 These findings highlight the decisive contribution of the aglycon to the good inhibition and account for the fact that the structure-based inhibitor design of glucose analog GPIs has mainly been focused on the anomeric substitution patterns. Nevertheless, to get a thorough insight into the structure-activity relationships, the exploration of the specificity of the sugar unit is also necessary. Early investigations on the inhibitory and binding properties of different monosaccharides indicated the superior effectiveness of Dglucose. 21, 22 Changes in the sugar configuration (e.g., for Dmannose 21 K i >100 mM against RMGPb) as well as removal or replacement of substituents of the glucose moiety (e.g., for 2deoxy-D-glucose 21 K i ¼27 mM, for D-xylose 21 K i ¼> 100 mM, for 3deoxy-3-fluoro-D-glucose 22 K i ¼200 mM against RMGPb) proved 1 2 3 4 5 6 7 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55   56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119 CAR6993_proof ■ 7 May 2015 ■ 1/9
Please cite this article in press as: Bokor E, et al., C-(2-Deoxy-D-arabino-hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and their evaluation as glycogen phosphorylase inhibitors, Carbohydrate Research (2015), http://dx.doi.org/10.1016/j.carres.2015.04.016 detrimental for the inhibition. Taking into account the crucial role of the aglycon in the efficiency of the glucose based inhibitors alterations of the sugar moiety in cases of some potent heterocyclic glucose derivatives were also examined to test whether the interactions of the anomeric substituent could compensate the impaired binding affinity of the glycon.
As part of this program D-xylose derived analogs of the best glucose based inhibitors were most often studied. Xylopyranosylidene-spiro-hydantoins, the first compounds investigated in this series, proved practically inactive. 23 Xylopyranosylidene-spiro-isoxazolines and oxathiazoles, 24 having the most potent aglycones of the glucopyranosyl series, 25e27 remained also ineffective. 24 Xylopyranosyl counterparts of N-(b-Dglucopyranosyl)-1,2,3-triazoles (e.g., 8 in Chart 1) as well as analogous derivatives of 5-thio-xylose and their oxidized variants (sulfoxides and sulfones) showed also negligible or no inhibition against RMGPb. 28 Very recently, C-b-D-xylopyranosyl-heterocycles were synthesized (e.g., 21 and 22) , and among them only the 2naphthyl substituted 1,2,4-triazole derivative 21 had modest activity towards RMGPb. 24 Other studies with N-b-D-glucopyranosyl-pyrimidines 15, 17 2e7 and 9e12 showed that replacement of the 3-OH group of the glucose moiety by fluorine caused very significant weakening of the inhibitions (see Chart 1 for the directly comparable pairs 2 and 9, 3 and 10, and 7 and 11, respectively). 29 Nevertheless, elongation of the aglycon by a hydrophobic group proved advantageous (compare 11 and 12) rendering compound 12 to be the first micromolar inhibitor of this class. 29 Furthermore, insertion of an axially oriented hydroxymethyl group into the C-3 position of the glucose part of 2 induced a slightly decreased inhibition (K i ¼27.1 mM against RMGPb) in spite of additional molecular interactions of the eCH 2 OH group that was evidenced by X-ray crystallography. 30 Additionally, in the frame of a study of conformationally restricted pseudonucleosides, an N-substituted spirothiohydantoin ring was constructed at the C-3 position of Dglucose, however, such compounds remained inactive against RMGPb. 31 Glucofuranosylidene-spiro-hydantoins 32 as well as some iminosugar derivatives were also studied to show no significant activity except 1,4-dideoxy-1,4-imino-arabinitol (DAB). 33 The phosphorolytic cleavage of glycogen catalyzed by GP is supposed to occur via a glycosyliumion-like transition sate. 34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 by X-ray crystallography for some iminosugar type GP inhibitors. 33 Glycals can also be considered as oxocarbenium ion analogs due to the resemblance of the shape of these molecules (half-chair conformation) to that of the glycosyl cation, as it was demonstrated earlier for glycosidase inhibitors. 35 Based on these considerations we set out to prepare 1-C-hetaryl-glucal derivatives to study their inhibitory potential against GP. Although D-glucal itself is a weak inhibitor of RMGPb (K i ¼80 mM), 21 it can be assumed that attaching a heterocycle to the C-1 carbon atom of the glucal may result in favorable interactions with the protein. In this paper we disclose our first steps towards this type of inhibitors and report the syntheses and enzymatic evaluation of each possible isomer of oxadiazoles appended to D-glucal by a CeC bond.
Results and discussion

Syntheses
For the preparation of the target compounds two main routes can be envisaged: a suitably functionalized glucal can be made first followed by the formation of the heterocycle in the final stage or, alternatively, the 1,2-double bond can be introduced into a preformed C-glucopyranosyl heterocycle. The rather scarce literature of 1-C-hetaryl pyranoid glycals 45e48 offers possibilities for both strategies and neither of them seems superior. 47 Since the 2,3,4,6tetra-O-benzoyl-b-D-glucopyranosyl cyanide 49 23 was shown to be a common precursor toward each isomer of C-glucopyranosyloxadiazoles 40, 39, 43, 50 synthesis and transformations of its unsaturated counterpart 25 (Scheme 1) were studied first.
Based on literature analogies 46, 47, 51, 52 DBU induced benzoic acid elimination from 23 as well as Zn/N-methylimidazole mediated reductive elimination 35, 53 of the 2,3,4,6-tetra-O-benzoyl-1-bromob-D-glucopyranosyl cyanide 49 (24) were probed to get the 1-cyanoglucal 25 (Scheme 1). The latter method proved to be more efficient both in terms of purity of the product and overall yields (compare yields under conditions a and b in Scheme 1 taking into account that 24 can be obtained almost quantitatively 49 ). By adaptation of a literature method 43 25 was then transformed into amidoxime 26, which was acylated by acid chlorides to give compounds 27 and 28 in high yields. Subsequent TBAF promoted ring closure 54 gave oxadiazoles 29 and 30, which were debenzoylated by the Zempl en protocol to furnish 5-aryl-3-(2 0 -deoxy-D-arabino-hex-1 0 -enopyranosyl)-1,2,4-oxadiazoles 31 and 32, respectively, in good yields.
For the preparation of the constitutionally reversed O-perbenzoylated 3-aryl-5-(2 0 -deoxy-D-arabino-hex-1 0 -enopyranosyl)-1,2,4oxadiazoles (35 and 36) both main strategies were investigated (Scheme 2). 1,3-Dipolar cycloaddition of in situ generated nitrile oxides 39, 50 to the O-perbenzoylated 1-cyano-glucal 25 took place chemoselectively to give unsaturated oxadiazoles 35 and 36.
Additionally, DBU induced b-elimination of PhCOOH from the appropriate O-perbenzoylated 3-aryl-5-b-D-glucopyranosyl-1,2,4oxadiazoles 39,50 33 and 34 was also performed. A comparison of the yields for 35 and 36 from 25 on route a and from 33 and 34 on route b, respectively, showed the latter method to be superior. Deprotection of 35 and 36 was carried out by the Zempl en method to yield 37 and 38, which proved identical with C-glucosyl-1,2,4oxadiazoles isolated as by-products in the base-catalyzed transesterification of compounds 33 and 34, respectively. 39 For the formation of 2-(2 0 -deoxy-D-arabino-hex-1 0 -enopyranosyl)-5-substituted-1,3,4-oxadiazoles (48e50) the easily available O-perbenzoylated 2-(b-D-glucopyranosyl)-5-substituted-1,3,4-oxadiazoles 40, 39 (39e41) were used as starting materials (Scheme 3). Contrary to the elimination of PhCOOH from 3-aryl-1,2,4-oxadiazole derivatives (33 and 34 in Scheme 2, route b) introduction of the double bond into the sugar moiety of 39e41 by using DBU failed (no or low conversions were observed at either rt. or reflux temperature in CH 2 Cl 2 , CHCl 3 and toluene). We speculate that this might be due to different acidity of the C-1-H bonds, however, no further investigations were devoted to verify this point. Thereafter, the bromination-reductive elimination sequence was followed to obtain the unsaturated derivatives 45e47. Bromination of 40 and 41 was smoothly accomplished to give 43 and 44, respectively, by using Br 2 under irradiation by a heat lamp. 55 Taking into account the susceptibility of the methyl group to be brominated under the above radical bromination conditions 56 transformation of 39 into 42 was achieved by using the KBrO 3 eNa 2 S 2 O 4 / CH 2 Cl 2 eH 2 O reagent-solvent system 57 where the methyl group remained intact. The brominated compounds 42e44 were then subjected to reductive elimination by Zn/N-methylimidazole to obtain 45e47, respectively, in good yields. Removal of the benzoyl protecting groups by the Zempl en method furnished the final products 48e50 in high yields.
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while the same signals appeared in the 5.8e6-1 ppm range for the deprotected derivatives 31, 32, 37, 38, 48e50. Characteristic 13 C resonances are collected in Table 1 to show the C-1 0 and C-2 0 signals for the double bond in the sugar rings as well as the C-2 or C-3 and C-5 peaks for the heterocycles.
Enzyme kinetic studies
The unprotected oxadiazoles 31, 32, 37, 38, and 48e50 were assayed against rabbit muscle glycogen phosphorylase b as described earlier 58 In conclusion, syntheses of D-glucals conjugated to each isomer of oxadiazoles by a CeC bond were carried out. These compounds could be prepared by introducing the double bond in the precursor glucopyranosyl cyanide followed by further manipulations to cyclize the aglycon or formation of the unsaturated sugar ring in the C-glucosyl heterocycle. Either base induced elimination of benzoic acid from the O-perbenzoylated starting compounds or Zn/Nmethylimidazole mediated reductive elimination from the 1bromoglucosyl precursor molecules could be applied for the formation of the hex-1-enopyranosyl rings. However, no general sequence of the above steps could be established, therefore, specific syntheses had to be elaborated for each target compound. None of the studied glucal derived oxadiazoles showed inhibition against RMGPb indicating that the binding of the these aglycons was not strong enough to override the detrimental effects of the changes in the sugar parts of the molecules.
Experimental
General methods
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Please cite this article in press as: A 5-aryl-2-(2 0 ,3 0 ,4 0 ,6 0 -tetra-O-benzoyl-b-D-glucopyranosyl)-1,3,4-oxadiazole (40 or 41, 2.0 g) was dissolved in anhydrous CHCl 3 (30 mL) in an Erlenmeyer flask, and bromine (3 equiv) and some solid K 2 CO 3 were added. The mixture was placed above a heat lamp (375 W, distance from the lamp 2e3 cm, height of the solution 1e2 cm), and refluxed. After total consumption of the starting material monitored by TLC (1:3 EtOAc-hexane) the mixture was diluted with CHCl 3 (100 mL) and extracted with 1 M aq Na 2 SO 3 solution (80 mL), satd aq NaHCO 3 solution (2Â80 mL) and with water (80 mL). The organic phase was dried over MgSO 4 , filtered and evaporated under diminished pressure. The residual crude product was purified either by crystallization or by column chromatography. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66   67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130 CAR6993_proof ■ 7 May 2015 ■ 6/9
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Please cite this article in press as: 2-Methyl-5-(2 0 ,3 0 ,4 0 ,6 0 -tetra-O-benzoyl-b-D-glucopyranosyl)-1,3,4-oxadiazole 40 (39, 0.85 g, 1.28 mmol) was dissolved in CH 2 Cl 2 (25 mL), and an aqueous solution of KBrO 3 (1.29 g, 7.70 mmol, 6 equiv in 25 mL water) was added. To the stirred heterogenous mixture an aqueous solution of Na 2 S 2 O 4 (1.34 g, 7.70 mmol, 6 equiv in 25 mL water) was added dropwise over 10 min. The mixture was then stirred at rt and the reaction was monitored by TLC (1:1 EtOAc-hexane). After disappearance of the starting material (1 d) the reaction mixture was diluted with CH 2 Cl 2 (50 mL), extracted with 1 M aq solution of Na 2 SO 3 (30 mL), with satd aq NaHCO 3 (2Â30 mL) and with water (30 mL), respectively. The organic phase was dried over MgSO 4 , filtered and evaporated under diminished pressure. The residue was purified by column chromatography (1:2 EtOAc-hexane) to yield 0.61 g (64%) white amorphous solid. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 
Enzyme assay
Glycogen phosphorylase b was prepared from rabbit skeletal muscle according to the method of Fischer and Krebs, 59 using dithiothreitol instead of L-cysteine, and recrystallized at least three times before use with a specific activity of 55 U/mg protein. Kinetic experiments were performed in the direction of glycogen synthesis as described previously. 58 Kinetic data for the inhibition of rabbit skeletal muscle glycogen phosphorylase were collected using 4 mM of a-D-glucose-1-phosphate constant concentrations of glycogen (1% w/v) and AMP (1 mM), and various concentrations of inhibitor. Inhibitor was dissolved in dimethyl sulfoxide (DMSO) and diluted in the assay buffer (final concentrations between 6.25 and 625 mM) (50 mM triethanolamine, 100 mM KCl, 1 mM EDTA and 1 mM dithiothreitol) so that the DMSO concentration in the assay should be lower than 1% .  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
